Suggested remit: To appraise the clinical and cost effectiveness of tezepelumab within its marketing authorisation for treating severe chronic rhinosinusitis with nasal polyps.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- STA Standard
- ID number:
- 6379
Provisional Schedule
- Committee meeting:
- 15 July 2026
- Expected publication:
- 25 September 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
- External Assessment Group:
- Newcastle NIHR TAR Team, Newcastle University
Stakeholders
- Companies sponsors
- AstraZeneca (tezepelumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Allergy UK
- Anaphylaxis UK
- Asthma + Lung UK
- Asthma Relief Charity
- NARA – The Breathing Charity
- Sinus UK
- SmellTaste
- South Asian Health Foundation
- Specialised Healthcare Alliance
- The Samter’s Society
- Professional groups
- Association of Respiratory Nurse Specialists
- Association for Respiratory Technology and Physiology
- Association of Surgeons of Great Britain and Ireland
- British Association of Otolaryngologists, Head & Neck Surgeons
- British Geriatrics Society
- British Society for Allergy and Clinical Immunology
- ENT UK
- National Heart and Lung Institute
- Primary Care Respiratory Society UK
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Sanofi (dupilumab)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Asthma, Allergy and Inflammation Research Trust
- British Association for Lung Research
- Cochrane Airways Group
- David Hide Asthma and Allergy Research Centre
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 December 2025 | Invitation to participate |
| 12 September 2025 - 10 October 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 12 September 2025 | In progress. Scoping commenced. |
| 12 October 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 12 October 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual